Barclays comes to the defense of Baxter (BAX -3.1%) this afternoon, upping the stock to...

|About: Baxter International Inc (BAX)|By:, SA News Editor

Barclays comes to the defense of Baxter (BAX -3.1%) this afternoon, upping the stock to Overweight on today's weakness. The stock was hit after the drug-maker said Phase III testing of its Gammagard treatment for Alzheimer's disease did not meet its co-primary endpoints.